Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023

慢性閉塞性肺疾患(COPD)治療薬の世界市場2019-2023

◆タイトル:Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023
◆商品コード:IRTNTR30709
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年1月18日
◆ページ数:118
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、慢性閉塞性肺疾患(COPD)治療薬の世界市場について調査・分析し、市場概要、市場環境、慢性閉塞性肺疾患(COPD)治療薬市場規模、製品別(併用療法、単剤療法)分析、種類別(慢性気管支炎、肺気腫)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・慢性閉塞性肺疾患(COPD)治療薬の世界市場概要
・慢性閉塞性肺疾患(COPD)治療薬の世界市場環境
・慢性閉塞性肺疾患(COPD)治療薬の世界市場動向
・慢性閉塞性肺疾患(COPD)治療薬の世界市場規模
・慢性閉塞性肺疾患(COPD)治療薬の世界市場:業界構造分析
・慢性閉塞性肺疾患(COPD)治療薬の世界市場:製品別(併用療法、単剤療法)
・慢性閉塞性肺疾患(COPD)治療薬の世界市場:種類別(慢性気管支炎、肺気腫)
・慢性閉塞性肺疾患(COPD)治療薬の世界市場:地域別市場規模・分析
・慢性閉塞性肺疾患(COPD)治療薬の北米市場規模・予測
・慢性閉塞性肺疾患(COPD)治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・慢性閉塞性肺疾患(COPD)治療薬のアジア太平洋市場規模・予測
・慢性閉塞性肺疾患(COPD)治療薬の主要国分析
・慢性閉塞性肺疾患(COPD)治療薬の世界市場:意思決定フレームワーク
・慢性閉塞性肺疾患(COPD)治療薬の世界市場:成長要因、課題
・慢性閉塞性肺疾患(COPD)治療薬の世界市場:競争環境
・慢性閉塞性肺疾患(COPD)治療薬の世界市場:関連企業情報(ベンダー分析)

About this market
COPD is a chronic non-communicable, lifestyle-related disease, which progresses continuously in the absence of medical intervention. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution. exposure to second-hand or passive smoking. smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status. and dietary factors, which lead directly or indirectly to COPD. Apart from lifestyle factors, there are factors such as old age and presence of rare genetic disorders. which contribute to the rising prevalence of COPD. Technavio’s analysts have predicted that the chronic obstructive pulmonary disease (COPD) drugs market will register a CAGR of almost 4% by 2023.
Market Overview
Strong pipeline and new drug approvals
The pipeline for the treatment of COPD includes several drug combinations, which can provide a wide range of therapeutic benefits. These drug combinations are presently in the late stages of development, with some expected to be launched in the market during the forecast period. These molecules combine the properties of drugs from different classes and have diversified therapeutic mechanisms of action and hence are expected to change the course of COPD treatment.
Low diagnosis rates for COPD
There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.
For the detailed list of factors that will drive and challenge the growth of the chronic obstructive pulmonary disease (COPD) drugs market during the 2019-2023, view our report.
Competitive Landscape
The chronic obstructive pulmonary disease (COPD) drugs market appears to be moderately concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Combination therapy – Market size and forecast 2018-2023
• Monotherapy – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
• Chronic bronchitis
• Emphysema
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical
PART 15: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global respiratory disorder drugs market
Exhibit 03: Segments of global respiratory disorder drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline molecules for COPD
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Product – Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Combination therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Combination therapy – Year-over-year growth 2019-2023 (%)
Exhibit 23: Monotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Monotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 25: Sales of monotherapy drugs 2015-2017 ($ millions)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 36: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Decision framework
Exhibit 41: Mechanism of action of budesonide/ glycopyrronium/formoterol triple combination
Exhibit 42: New drug approvals for COPD
Exhibit 43: US FDA-approved fixed-dose combination LABAs and LAMAs
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Examples of advanced nebulizers
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AstraZeneca – Vendor overview
Exhibit 52: AstraZeneca – Business segments
Exhibit 53: AstraZeneca – Organizational developments
Exhibit 54: AstraZeneca – Geographic focus
Exhibit 55: AstraZeneca – Key offerings
Exhibit 56: Boehringer Ingelheim – Vendor overview
Exhibit 57: Boehringer Ingelheim – Business segments
Exhibit 58: Boehringer Ingelheim – Organizational developments
Exhibit 59: Boehringer Ingelheim – Geographic focus
Exhibit 60: Boehringer Ingelheim – Segment focus
Exhibit 61: Boehringer Ingelheim – Key offerings
Exhibit 62: GlaxoSmithKline – Vendor overview
Exhibit 63: GlaxoSmithKline – Business segments
Exhibit 64: GlaxoSmithKline – Organizational developments
Exhibit 65: GlaxoSmithKline – Geographic focus
Exhibit 66: GlaxoSmithKline – Segment focus
Exhibit 67: GlaxoSmithKline – Key offerings
Exhibit 68: Novartis – Vendor overview
Exhibit 69: Novartis – Business segments
Exhibit 70: Novartis – Organizational developments
Exhibit 71: Novartis – Geographic focus
Exhibit 72: Novartis – Segment focus
Exhibit 73: Novartis – Key offerings
Exhibit 74: Teva Pharmaceutical – Vendor overview
Exhibit 75: Teva Pharmaceutical – Business segments
Exhibit 76: Teva Pharmaceutical – Organizational developments
Exhibit 77: Teva Pharmaceutical – Geographic focus
Exhibit 78: Teva Pharmaceutical – Segment focus
Exhibit 79: Teva Pharmaceutical – Key offerings
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations



【掲載企業】

AstraZeneca、Boehringer Ingelheim、GlaxoSmithKline、Novartis、Teva Pharmaceutical

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[慢性閉塞性肺疾患(COPD)治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆